Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 1, 1998, Pages 84-87

  Mani, Sridhar ^a,b   Iyer, Lalitha ^a   Janisch, Linda ^a   Wang, Xiaolin ^a   Fleming, Gini F ^a   Schilsky, Richard L ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

9 Aminocamptothecin; CD formulation; Oral; Pharmacokinetic; Phase I; Topoisomerase inhibitor

Indexed keywords

9 AMINOCAMPTOTHECIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CANCER; BREAST CANCER; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DISPERSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPONATREMIA; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CAMPTOTHECIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0031977028     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050789     Document Type: Article

References (16)

1. Bendixen C, Thomsen B, Aisner J, Westergaard O (1990) Camptothecin-stabilized topoisomerase-I DNA adducts cause premature termination of transcription. Biochemistry 29: 5613
2. D'Arpa P, Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163
3. Edman K, Ericksson B, Nordle Ö (1995) Study #94 122 (Confidential Document #9520730, 20 June 1995). Pharmacia, Kalamazoo
4. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment therapy. In: Gibaldi M, Perrier D (eds) Pharmacokinetics. Marcel Dekker, New York Basel, p 409
5. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723
6. Moore A, Imondi A, L'Heureux D (1997) Preclinical evaluation of three dosage schedules of 9-aminocamptothecin (9-AC) for the treatment of spontaneous lymphoma in dogs (abstract), Proc Am Assoc Cancer Res 38: 75
7. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS Jr, Giovanella BC (1992) Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52: 3980
8. Pastori A, Farao M, Geroni C, Porro MG, Grandi M (1997) Antitumor activity of 9-aminocamptothecin (9-AC) by s.c. and oral route (abstract). Proc Am Assoc Cancer Res 38: 18
9. Potmcsil M, Giovanella BC, Liu LF1 (1991) Preclinical studies of DNA topoisomerase I targeted 9-amino and 10,11-methylenedioxy camptothecins. In: Potmesil M. Kohn KW (eds) DNA topoisomerases in cancer. Oxford University Press, New York, p 299
10. Potmesil M, Giovanella BC, Wall ME (1993) Preclinical and clinical development of DNA topoisomerase I inhibitors in the United States. In: Andoh T (ed) International symposium on DNA topoisomerase in chemotherapy. CRC Press, New York, p 301
11. Sparreboom A, Stoter G, Loos WJ, Nooter K, Punt CJA. Calajori E, Verweij J (1997) Oral bioavailability of 9-aminocamptothecin in adult patients with solid tumors (abstract). Proc Am Assoc Cancer Res 38: 75
12. Supko JG, Plowman J, Dykes DJ, Zaharko DS (1992) Relationship between the schedule dependence of 9-amino-20 (s)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokineties (abstract). Proc Am Assoc Cancer Res 33: 432
13. Takimoto CH, Klecker RW, Dahut WL, Yee LK, Strong JM, Allegra CJ, Grem JL (1994) Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr 655: 97
14. Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL (1997) Pharmacodynamics and pharmacokineties of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15: 1492
15. Wani MC, Ronman PE, Lindley JT, Wall ME (1980) Plant antitumor agents: Synthesis and biological activity of camptothecin analogues. J Med Chem 23: 554
16. Wani MC, Nicholas AW, Wall ME (1986) Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. J Med Chem 29: 2358 2363